Evidence map›Paper›PMID 40777979›Full record

SynthesisAfrican health sciences2024

Are TP53 Arg72Pro and MDM2 T309G polymorphisms associated with bladder cancer risk? A meta-analysis.

Rym-Khadidja Abderrahmane, Zohra Touala-Chaila, Khedidja Benseddik, Nihed Hassani, Hind Drider, Imene Derbouz-Draoua, Djebaria Naima Meroufel

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rym-Khadidja AbderrahmaneUniversité des Sciences et de la Technologie d'Oran Mohamed-Boudiaf USTOMB El Mnaouar, BP 1505, Bir El Djir 31000, Oran, Algérie.
Zohra Touala-ChailaUniversité des Sciences et de la Technologie d'Oran Mohamed-Boudiaf USTOMB El Mnaouar, BP 1505, Bir El Djir 31000, Oran, Algérie.
Khedidja BenseddikLaboratoire de la Génétique Moléculaire et Cellulaire (LGMC) USTOMB El Mnaouar, BP 1505, Bir El Djir 31000, Oran, Algérie.
Nihed HassaniUniversité des Sciences et de la Technologie d'Oran Mohamed-Boudiaf USTOMB El Mnaouar, BP 1505, Bir El Djir 31000, Oran, Algérie.
Hind DriderUniversité des Sciences et de la Technologie d'Oran Mohamed-Boudiaf USTOMB El Mnaouar, BP 1505, Bir El Djir 31000, Oran, Algérie.
Imene Derbouz-DraouaUniversité des Sciences et de la Technologie d'Oran Mohamed-Boudiaf USTOMB El Mnaouar, BP 1505, Bir El Djir 31000, Oran, Algérie.
Djebaria Naima MeroufelUniversité des Sciences et de la Technologie d'Oran Mohamed-Boudiaf USTOMB El Mnaouar, BP 1505, Bir El Djir 31000, Oran, Algérie.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We still do not know the exact cause of bladder cancer (BC). Objectives: Evaluation of the effect of TP53 Arg72Pro and MDM2 T309G polymorphisms with the risk of Bladder cancer. Methods: A literature search was conducted followed by a meta-analysis. Then, sensitivity and subgroup analyses were performed. 14 relevant studies were included in the quantitative analysis. Results: No statistically significant associations were found. The results of the subgroup analysis revealed a significant association in the Turkish population for T309G: G vs. T (P-value= 0.015; OR 95%CI= 1.51 [1.084; 2.125]), GG vs.TT (P-value= 0.009; OR 95% CI= 2.60 [1.262; 5.370]). Sensitivity analysis revealed a significant association between the Arg72Pro: C vs. G (OR= 1.22, 95% CI [1.05; 1.40]), CC vs. GG (OR= 1.54; 95% CI [1.13; 2.09]), CC+CG vs. GG (OR= 1.24; 95% CI [1.01; 1.53]), CC vs. CG+GG (OR= 1.33; 95% CI [1.01; 1.74]), and T309G: G vs. T (OR= 1.30; 95% CI [1.07; 1.57]), GG vs. GT+TT (OR= 1.53; 95% CI [1.10; 2.11]), GG vs. GT (OR=1.44; 95% CI [1.02; 2.02]), GG vs. TT (OR= 1.88; 95% CI [1.25; 2.82]) with BC occurrence. Conclusion: The T309G polymorphism was found to be a predisposing allele for BC in Turkish population.

Indexed as

Genetic Predisposition to DiseaseProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Urinary Bladder NeoplasmsGenotypeHumansPolymorphism, GeneticPolymorphism, Single NucleotideRisk FactorsTurkeyMDM2 protein, humanProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53Arg72ProBladder cancer (BC)MDM2Meta-analysispolymorphismT309GTP53

Identifiers

PMID40777979
PMCPMC12327109

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.